Drugs / GSK3862995B
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06979518 | May 2025 → Apr 2026 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT06154837 | Nov 2023 → Dec 2026 expected | chronic obstructive pulmonary disease | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07201051 | Oct 2025 → May 2027 expected | bronchiectasis | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3862995B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06154837 ↗ |